A Randomized, Double-blind, Positive-drug Parallel Controlled, Multicenter Phase III Trial of the Efficacy and Safety of S086 Tablets in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Latest Information Update: 04 Nov 2022
Price :
$35 *
At a glance
- Drugs Alisartan/sacubitril-Shenzhen Salubris Pharmaceuticals (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 13 Jul 2022 New trial record
- 28 Jun 2022 According to a SalubrisBio media release, first patient has been dosed in this study.